[Reporter’s View] Aging society redefines new drug value

Korea has entered a super-aged society. With life expectancy on the rise, the challenges healthcare must address are evolving as well. The focus is no longer simply on helping people live longer, but on enabling them to maintain healthy, independent lives for as long as possible. This shift is already reshaping not only clinical practice but also the development of innovative new drugs and clinical trial designs.

Traditionally, the value of a new medicine has largely been measured by how much it delays disease progression compared with existing therapies. In oncology, overall survival (OS) and progression-free survival (PFS) have been the benchmark endpoints. For cardiovascular therapies, reductions in cardiovascular events have been key, while delaying the need for dialysis has been a major outcome for chronic kidney disease treatments. These endpoints remain the gold standard for demonstrating clinical efficacy.

However, recent global clinical trials reveal a noticeable shift. Studies are increasingly incorporating patient-reported outcomes (PROs), health-related quality of life (QoL), time to symptom deterioration, reductions in hospitalizations and readmissions, and preservation of physical function as primary or key secondary endpoints—measures that reflect outcomes patients directly experience during treatment.

Quality of life, once regarded as a supplementary outcome, has now become one of the principal measures used to demonstrate the clinical value of innovative therapies.

This evolution reflects more than a change in clinical trial design. It signals a broader transformation in what healthcare seeks to achieve in a super-aged society. For older patients, treatment success cannot simply be defined by extending survival by a few additional months. Whether patients can maintain their daily routines, avoid repeated hospitalizations, and continue living independently while receiving treatment is becoming increasingly important.

The same trend is evident in the field of disease prevention. Modern vaccines and preventive therapies are no longer evaluated solely on their ability to prevent infection. They are increasingly assessed on their capacity to reduce progression to severe disease, prevent hospitalization, and help individuals maintain healthy daily lives. The growing emphasis on prevention strategies as a means of extending healthy life expectancy while reducing the burden on healthcare systems reflects this broader shift.

Ultimately, prevention and treatment are converging toward the same objective. Prevention seeks to preserve good health for as long as possible, while treatment aims to manage disease in a way that allows patients to maintain their quality of life. Preventing disease, detecting it early, providing appropriate treatment, and helping patients continue their daily lives afterward are becoming the defining principles of modern healthcare across the entire continuum of care.

As a result, the competitiveness of innovative medicines can no longer be judged solely by their therapeutic efficacy. While extending survival remains critically important, equal attention is now being paid to how significantly a treatment improves patients' lives.

Indeed, global pharmaceutical companies are increasingly presenting quality-of-life data and patient-reported outcomes in clinical trials to demonstrate the value of their therapies. In many respects, this represents one of the earliest indicators of the direction healthcare must take in a super-aged society.

Korea’s transition into a super-aged society is demanding a new role for innovative medicines. As contemporary clinical trials increasingly recognize quality of life, preservation of function and reductions in hospitalization as key measures of treatment success, regulatory approval, reimbursement and healthcare policy must also evolve to reflect these changes. Assessing not only how long patients live, but how profoundly a therapy improves their lives is the new challenge a super-aged society presents to healthcare.